Condition: Recurrent/ Metastatic Olfactory Neuroblastoma · Sponsor: National Cancer Center Hospital East
This trial evaluates the efficacy and safety of nivolumab monotherapy in patients with recurrent or metastatic olfactory neuroblastoma that is difficult to treat with curative intent. Specifically, nivolumab 240 mg will be administered on Day 1 and Day 15 of each cycle, or nivolumab 480 mg will be administered on Day 1 of each cycle, and this will be continued until disease progression. One cycle is 28 days. The decision on which treatment to administer will be made through consultation between the participant in this trial and their attending physician.
This description comes directly from the study's public registry record.
Yuta Hoshi, MD · +81-4-7133-1111 · yuhosh@east.ncc.go.jp
Always discuss trial participation with your own doctor first.
| National Cancer Center Hospital East | Kashiwa, Chiba, Japan | Recruiting |
| Jichi Medical University Hospital | Shimotsuke, Tochigi, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07100704